1) Strategy & Leadership
- CEO August Troendle noted an elevated cancellation rate in Q4, leading to a lower than expected net book-to-bill ratio of 1.04.
- Despite cancellations, the overall business environment is rated as adequate and improving.
- The company continues to see good opportunities, particularly in oncology and metabolic areas, although cancellations were skewed towards metabolic projects.

2) Financial & Segment Results
- Q4 revenue reached $708.5 million, a 32% increase YoY, while full-year revenue was $2.53 billion, up 20% from 2024.
- Net new business awards in Q4 were $736.6 million, a 39.1% increase YoY, with a full-year total of $2.65 billion, up 18.7%.
- Ending backlog as of December 31, 2025, was approximately $3 billion, a 4.3% increase YoY, with an expected $1.9 billion to convert to revenue in the next twelve months.
- Q4 EBITDA was $160.2 million (22.6% margin), up from $133.5 million (24.9% margin) YoY. Full-year EBITDA was $557.7 million, a 16.1% increase YoY.
- Net income for Q4 was $135.1 million, a 15.5% increase YoY, with full-year net income at $451.1 million, an 11.6% increase YoY.

3) Problems / Headwinds
- Elevated cancellations in Q4 were the highest in over a year, impacting the net book-to-bill ratio and overall revenue expectations.
- Cancellations were widespread, particularly in the metabolic area, but no single large project was responsible.
- The company faced pressure on EBITDA margins due to higher reimbursable costs driven by the therapeutic mix.

4) Operational Plans & Guidance
- For 2026, the company expects total revenue between $2.755 billion and $2.855 billion, representing growth of 8.9% to 12.8% over 2025.
- EBITDA guidance for 2026 is set between $605 million and $635 million, reflecting growth of 8.5% to 13.9%.
- Net income is projected to be between $487 million and $511 million, with expected earnings per diluted share of $16.68 to $17.50.
- The company anticipates accelerated hiring in 2026, with mid to high single-digit growth in headcount.

5) Investor Angle & Missing Information
- The company did not provide specific guidance on direct service revenue or detailed metrics on RFP activity and win rates.
- There was no mention of how the elevated cancellation rates might impact future revenue projections beyond 2026.

Bottom line: Medpace Holdings, Inc. has demonstrated strong revenue growth and a solid backlog, but elevated cancellation rates in Q4 present a near-term challenge. The company is optimistic about its operational plans and guidance for 2026, indicating continued growth potential, albeit with caution regarding the impact of cancellations and market dynamics.